Additional mutations, such as those in Ras-pathway downstream effectors, including FGFR1, TP53, LIN28, PTPRD, SHANK2, BRCA2, MAPK, LMO1, and ARID1A/1B, have been identified at lower frequencies in neuroblastoma [3,6,49,57,66,67,68]. This evidence concerns the gene TP53 and neuroblastoma.